Overview

GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia

Status:
Recruiting
Trial end date:
2022-12-25
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of inhaled molgramostim nebuliser solution in patients with COVID-19 pneumonia.
Phase:
Phase 2
Details
Lead Sponsor:
University of Giessen
Treatments:
Molgramostim
Pharmaceutical Solutions
Sargramostim